The Licensing Executives Society International (LESI) is an association of 32 national and regional societies, each composed of men and women who have an interest in the transfer of technology, or licensing of intellectual property rights - from technical know how and patented inventions to software, copyright and trademarks.
LES ANZ Annual Conference 2009
LESI Annual Meeting 2009
Report of Study on Distribution Channels, Part "Safe Medicines through Parallel Trade" In 2006, DG Enterprise and Industry launched a study to assess aspects of patient safety related to parallel trade with medicines. An external contractor, Europe Economics, has now presented results of the study to the European Commission after Member States and stakeholders had the opportunity to provide data and views. The report includes a contribution to an assessment of social, economic and environmental impacts on various policy options to address any possible shortcomings. The report of the contractor, Europe Economics, and its annexes are now made publicly available. [http://ec.europa.eu/enterprise/pharmaceuticals/pharmacos/docs/doc2008/2008_10/report13may_corr.pdf] Young Members Task Force LESI has formed a task force to further meet the networking and professional needs of members under the age of forty (40). Goals of this working group include: Increasing the number of active members under the age of 40 within LES member societies. Encouraging participation and networking by young members at LESI events through organization of unique educational and social programs; and, Mentoring young executives for participation and leadership at LESI Board, Delegate and Committee levels as well as to make LESI officers aware of the interest, accomplishments and contributions of younger members. If you are under the age of 40 and are interested in participating, please contact the Task Force at: youngmembers@lesi.org. A first organizational meeting is planned in conjunction with the LESI Delegates Meeting and LES USA & Canada Annual Meeting in September 2009. To find out how to participate in the next Graduate Student Business Plan Competition in May 2009, click here.
A recent decision of the United States Supreme Court will have a profound impact on organizations that license intellectual property, either in or out. The decision, MedImmune v. Genentech, addresses an important issue: when can a licensee challenge a patent licensed under a technology transfer agreement? In the decision, the Supreme Court made it significantly easier for patent licensees to challenge such patents. The article provides some historical background, explains the decision, and suggests terms that might mitigate the damage done to licensors.
- Non-Member Subscription - September 2008 Issue - Advertise in les Nouvelles - Submission Guidelines - Archive / Search Featured Articles - Bayh-Dole: Don't Turn Back the Clock - Goddar-Mohnkopf: Agreements on University Research Cooperation Between Industry and University in Germany - Revised Berlin Contract